ProKidney's Cash Barely Outlasts Its Pivotal Kidney Cell Therapy Readout
The company's third-quarter update puts its money and its Phase 3 data deadline within a few months of each other, as it also enlarges the trial.
ProKidney ended the third quarter of 2026 with $141.9 million in cash, which the company says covers its spending until around the middle of 2027. Management expects the pivotal data for its kidney cell therapy rilparencel in the second quarter of 2027, so the cash and the readout sit only slightly apart.
The figures came in the US company's results on 12 November. The quarterly net loss widened to $51.8 million, and cash declined over the period. The material available does not give the prior-period comparisons.
The data in question come from PROACT 1 (REGEN-006), a Phase 3 study of rilparencel in people with advanced chronic kidney disease and type 2 diabetes. The readout will be based on the rate of change in kidney function, measured as eGFR slope.
ProKidney also enlarged the study. It now expects more than 500 patients in the confirmatory analysis, up from 470 in the earlier plan, and expects to finish enrolling them in the first quarter of 2027. The summary does not explain the increase, and it does not describe the comparator, the full trial design or the regulatory route to approval.
Why it matters
- The stated cash runway ends close to the guided data window, so the readout's timing is tied closely to the company's funding position.
- The larger confirmatory cohort, more than 500 patients versus 470, changes the study's scale, though the reasons and any effect on a future filing are not disclosed.
- The material does not set out the company's financing or partnering plans, so any funding arrangements around the readout are not yet known.
Company's press release (SEC filing): Prokidney Corp. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
IRulya Therapeutics reports $105.2M cash as LAM-001 Phase 2 readouts approach
Cerenome reports first CNSide revenue and completes enrolment in Phase 2 glioblastoma trial
BeyondSpring wins FDA Fast Track for plinabulin plus docetaxel in post-immunotherapy NSCLC
Valneva: 94% of adults still seroresponders five years after single IXCHIQ dose
GH Research posts $46.6M nine-month loss as GH001 depression programme nears pivotal stage
